| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Oncology-Clinical Diagnosis: Solid TumorsNeuroendocrine and Head & Neck Cancers |
1 U Hospital Bonn, Bonn, Germany
460
Objectives: Tumor-related survival is reduced in patients with well-differentiated thyroid carcinoma (DTC) suffering from distant metastases. The aim of this retrospective study was to evaluate the impact of synchronous versus metachronous distant metastases on DTC-related survival in patients with DTC.
Methods: The institutional database was retrospectively searched for patients with DTC and the presence of distant metastases. Patients with follow-up of at least one year and with known survival status at the end of follow-up were included.
Results: The median follow-up was 7.0 years. 51 patients (57.3 %) suffered from distant metastases 
6 months after initial diagnosis of DTC (synchronous), 38 patients (42.7 %) developed distant metastases > 6 months after diagnosis of DTC (metachronous). The group of synchronous distant metastases did not differ significantly from the group with metachronous metastases regarding age, gender, histology, T-classification and the presence of lymph node metastases (p=0.21, p=0.66, p=0.83, p=0.94, p=0.83). The 10-year survival rate after diagnosis of distant metastases was 64.5 % in patients with synchronous metastases compared to only 40.8 % in patients with metachronous metastases (p=0.001). Age 
45 years was also associated to DTC-related death (p=0.001). Gender, histology, T-classification, the presence of lymph node metastases or bone metastases had no impact on patients' outcome (p=0.38, p=0.33, p=0.30, p=0.89, p=0.80).
Conclusions: Apart from age 45 years, metachronous development of distant metastases is accompanied with significantly worse outcome (10-year survival 40.8 %) than in synchronous metastases (10-year survival 64.5 %).
| ||||||||||||||||||||||||||||
